Welcome to our dedicated page for Biofrontera news (Ticker: BFRIW), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. develops and commercializes photodynamic therapy in dermatology, centered on Ameluz® aminolevulinic acid topical gel and the RhodoLED® red-light lamp platform. The company’s updates cover U.S. commercialization of Ameluz PDT for actinic keratoses, revenue performance, and clinical development for additional dermatology uses including actinic keratoses on other body areas, superficial basal cell carcinoma, and acne vulgaris.
Recurring developments also include FDA application activity, study results, patent and intellectual-property proceedings, and corporate updates tied to Biofrontera’s U.S. assets and capital structure. The company’s common stock trades as BFRI and its warrants trade as BFRIW on Nasdaq.
Biofrontera Inc. (Nasdaq: BFRI; BFRIW) announced a successful private placement, raising $15 million through the sale of 2,857,143 shares and warrants to an institutional investor. Each share and accompanying warrant were priced at $5.25 under Nasdaq regulations. The warrants are immediately exercisable and will expire five years from issuance. Biofrontera must file a registration statement with the SEC within 15 days and ensure it's effective within 90 days.
Biofrontera Inc. (Nasdaq: BFRI) reported a 33% increase in Q3 2021 revenues to $4.3 million and a 45% increase year-to-date to $14.9 million, driven by strong sales of Ameluz®. The company raised $18 million through an IPO and a $15 million private placement. However, operating expenses surged to $20.4 million, leading to a net loss of $16.0 million. Despite the financial strain, management emphasized the positive sales trend, indicating recovery from the COVID-19 pandemic and continued clinical studies for Ameluz®. Cash reserves stood at $1.7 million as of September 30, 2021.
Biofrontera announced a securities purchase agreement with an institutional investor for 2,857,143 shares and warrants to purchase an equal number of shares at a price of $5.25 per share. This private placement is expected to generate approximately $15 million in gross proceeds, closing on or about December 1, 2021. The warrants are immediately exercisable and will expire in five years. The company must file a registration statement with the SEC within 15 days to cover the resale of these securities.